YahooOctober 9, 2026 at 1:11 PM NY18 Days Ago
Alumis snags set of Phase III psoriasis pill victories, but analysts lukewarm on impact
If envudeucitinib gains approval, it will join an increasingly competitive market flanked by drugs like J&J’s Icotyde, Amgen’s Otezla and BMS’ Sotyktu.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Yahoo
